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Free and esterified carnitine in continuous ambulatory peritoneal
dialysis patients. Free, acetyl-, medium- and long-chain acylcarnitine and
total plasma carnitine concentrations were measured in eight continuous
ambulatory peritoneal dialysis (CAPD) patients and eight age- and
sex-matched healthy controls. Daily loss of carnitine was also quantified in
both groups, by analysis of urine and dialysis fluid. Plasma total carnitine
concentration in CAPD patients was not significantly different from
controls (42.8 1.6 and 43.1 2.3 irmol/liter, respectively). However, the
plasma free carnitine concentration of CAPD patients was significantly
lower than that of controls (28.5 1.4 and 36.2 2.5 jrmol/liter,
respectively; P < 0.05). No difference in the daily loss of total carnitine was
found between CAPD patients and controls (269.7 30.0 and 240.5
33.0 jrmol, respectively), but the daily loss of free carnitine was signifi-
cantly greater in CAPD patients (175.8 17.3 and 105.8 16.4 rmol,
respectively; P < 0.05). The ratio of total acylcarnitine (acetyl-, medium-
and long-chain acylcarnitine) to free carnitine was significantly greater in
plasma of CAPD patients than in controls (P < 0.01) and was lower in
daily fluid losses (P < 0.001). These ratio differences suggests that an
alteration in acyl group metabolism is occurring in CAPD patients. This
may be attributable to an accumulation of medium- and long-chain
acylcarnitine in liver of CAPD patients which would be exchanged for
plasma free carnitine and/or to a differential loss of free and acylcarnitine
across the peritoneal cavity.
Carnitine is a naturally occurring compound which is involved
not only in muscular energy metabolism but also in overall cellular
metabolism. It is an essential factor in long-chain fatty acid
oxidation, facilitating the translocation of fatty acyl groups across
the inner mitochondrial membrane [1]. Carnitine may also regu-
late the cytosolic/mitochondrial acyl-C0A/CoASH ratio, by buff-
ering excess acyl group formation as a result of an impairment in
the cellular metabolism [21 or art increase in the rate of cellular
energy metabolism [3], and by doing so may prevent the inhibition
of many cellular reactions which depend on existence of a viable
pool of CoASH. Carnitine has become of interest in renal failure
because it has been shown that patients with end-stage renal
failure on hemodialysis have subnormal plasma and muscle free
carnitine and/or elevated acylcarnitine concentrations [4—81, al-
though the decline in muscle carnitine concentration has not been
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consistently confirmed [9, 10]. It is possible that these deficiencies
attributed to the loss of carnitine during hemodialysis could
contribute to the muscular fatiguability and weakness that renal
failure patients experience. Whether a similar situation exists in
patients undergoing continuous ambulatory peritoneal dialysis
(CAPD) is unclear. Previous studies have shown plasma carnitine
of CAPD patients to be comparable [6, 7, 11—13], towards being
lower [8] or significantly lower [14] compared with controls.
However, the controls in these previous studies were not age- and
sex-matched, which would have been desirable since plasma
carnitine is influenced by these two factors [15, 16], and may
therefore explain these equivocal findings.
The aims of the present study therefore were to assess the
plasma carnitine status of CAPD patients and to quantify the daily
loss of carnitine in this patient group compared with age- and
sex-matched healthy control subjects.
Methods
Eight patients (mean age 43.6 4.8 years; range 20 to 60 years;
Table 1) undergoing CAPD treatment (mean duration 27 months
14; range 4 to 120 months) were recruited from those attending
the CAPD out-patient clinic and matched with age- and sex-
healthy controls. The mean age of controls was 43.3 4.7 years
(range 20 to 59 years; Table 1). A 10 ml sample of venous blood
was obtained at least seven hours post-prandially from an ante-
cubital vein and was mixed with lithium heparin. Following
centrifugation (10 mm at 3,000 rpm), the plasma was snap frozen
in liquid nitrogen and stored at —80°C.
Both controls and CAPD patients undertook a 24-hour urine
collection using a 2 liter container containing 5 ml of a 0.67
mol/liter thymol solution in isopropanol. CAPD patients also
collected their dialysate fluids over the same period as their
24-hour urine sample. Following collection, the contents of each
dialysis bag and urine collection were pooled, mixed thoroughly
and 2 aliquots (10 ml) of each fluid were removed, snap frozen in
liquid nitrogen and stored at —80°C.
Sample aliquots of plasma, urine and peritoneal dialysis fluid
were extracted with chloroform/methanol (3/2, vol/vol). After
evaporation, the residue was dissolved in 0.1 mol/liter KOH,
incubated at 50°C for two hours and, subsequent to neutralization
with 0.5 mol/liter HC1, used for determination of total carnitine
using an enzymatic assay containing radioisotopic substrate, as
described previously [17]. Free carnitine was determined by
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Table 1. Demographic data relating to the study patients/controls 50
No. Sex
Age
years
Height
cm
Weight
kg
Time on
dialysis,
months Diagnosis'
1 M 59/58 171/177 64/75 5 Myelomatosis with CRF
2 F 45/46 162/177 64/49 31 CRF uncertain etiology
3 F 52/51 162/160 85/69 4 CRF uncertain etiology
4 M 37/37 192/177 90/77 120 CRF uncertain etiology
5 F 20/20 167/155 79/48 7 Glomerulonephritis
6 F 44/43 157/164 85/60 8 CRF uncertain etiology
7 F 60/59 153/169 57/70 7 Glomerulonephritis
8 M 32/32 180/178 67/85 30 Glomerulonephritis
a Abbreviation is chronic renal failure
dissolving the residue in water. Concentrations of acetylcarnitine
were measured in 0.5 mol/liter perchioric acid deproteinized
plasma, urine and peritoneal dialysis fluid using an enzymatic
assay containing radioisotopic substrate, as described previously
[18]. All measurements were performed in duplicate. Total acyl-
carnitine concentrations were obtained by subtracting free carni-
tine from total carnitine concentrations. Medium- and long-chain
acylcarnitine concentrations were obtained by subtracting free
carnitine and acetylcarnitine from total carnitine concentrations.
The daily loss of free, acetyl, medium- and long-chain acylcarni-
tine and total carnitine in each CAPD patient was calculated by
summing the loss in dialysate and urine. For each control, the
daily loss in urine was used. Renal and peritoneal clearances were
calculated according to the equation: clearance (mI/mm) = [urine
or peritoneal dialysis fluid concentration (j.rmol/liter) * urine or
peritoneal dialysis fluid volume (ml)]/[plasma concentration
(xmol/liter) * 1440 minutes].
The data were analyzed using Student's unpaired (-test (two-
tailed). Values in the text and Figures represent means SEM.
Results
The plasma total carnitine concentration of CAPD patients was
no different from that of controls (42.8 1.6 and 43.1 2.3
xmol/liter, respectively; P > 0.05; Fig. 1). However, plasma free
carnitine concentration of CAPD patients was significantly lower
than that of controls (28.5 1.4 and 36.2 2.5 mo1/liter,
respectively; P < 0.05; Fig. I). Though plasma acetylcarnitine
concentrations did not differ between the two groups (Fig. 1), this
ester represented only 40% of the total plasma esterified carnitine
in CAPD patients, but 70% of that in the controls. Comparison of
plasma medium- and long-chain acylcarnitine concentration re-
vealed a significantly greater concentration in CAPD patients
compared with controls (8.56 1.93 and 2.39 0.93 1xmol/liter,
respectively; P = 0.01; Fig. 1), the excess being of a similar
magnitude to the deficit in plasma free carnitine. The total plasma
acyl (acetyl-, medium- and long-chain acylcarnitine) to free car-
nitine ratio was significantly greater in CAPD patients compared
with controls (0.52 0.08 and 0.20 0.05, respectively; P < 0.01).
This was attributable to the lower plasma free carnitine concen-
tration and greater plasma medium- and long-chain carnitine
concentration in CAPD patients.
Figure 2 A and B show the renal and peritoneal clearances,
respectively, calculated in CAPD patients. Calculations of cumu-
lative (renal + peritoneal) clearances showed comparable total
carnitine clearance between the two groups (Fig. 2C). However,
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Fig. 1. Concentrations of total, free, acetyl-, medium- and long-chain acyl-
camitine in plasma from continuous ambulatoty peritoneal dialysis patients(, CAPD) and age- and sex-matched healthy controls (1111). Values repre-
sent means SCM. < 0.05, significantly different from controls.
the cumulative (renal + peritoneal) free and acetylated carnitine
clearances in CAPD patients were greater than the renal clear-
ances in controls (P < 0.01; Fig. 2C) and the medium- and
long-chain acylcarnitine clearance was lower (P < 0.01; Fig. 2C).
Despite the significantly lower daily loss of total carnitine via
urine by CAPD patients compared with controls (63.4 17.8 and
240.3 33.0 xmol, respectively; P < 0.001; Fig. 3A), the
cumulative loss of total carnitine via urine and peritoneal dialysis
fluid revealed no significant difference between CAPD patients
and controls (269.6 30.0 and 240.3 33.0 jxmol, respectively; P
> 0.05; Fig. 3C). This was mainly attributable to the fivefold
greater free carnitine daily loss by CAPD patients via peritoneal
dialysis fluid (148.2 18.8 jxmol; Fig. 3B) when compared with
their corresponding loss via urine (31.7 11.2 xmol; 3A). The
loss of free carnitine via peritoneal dialysis fluid was also the main
contributor to the significantly greater cumulative loss of free
carnitine by CAPD patients when compared with controls (175.8
17.3 and 105.8 16.4 ixmol, respectively; P < 0.05; Fig. 3C).
The ratio of total acylcarnitine to free carnitine in daily combined
fluid losses (urine plus peritoneal dialysis fluid) were significantly
lower in CAPD patients compared with controls (0.50 0.05 and
1.36 0.14, respectively; P < 0.001).
Discussion
The major findings of present study were, firstly, that patients
who had undergone CAPD treatment for a mean duration of 27
months have a significantly lower plasma free carnitine concen-
tration compared to a control group matched by age and sex. Most
previous studies have shown comparable plasma free carnitine
concentrations in CAPD patients [6, 7, 11—13]. Only one previous
study has shown a significantly lower plasma free carnitine
concentrations in CAPD patients [141. Secondly, the measure-
ment of daily carnitine loss via analysis of urine and dialysis fluids
showed a significantly greater loss of free carnitine and acetylcar-
nitine in CAPD patients compared with controls. These latter
findings were apparent despite the fact that the daily losses of
total carnitine of both groups were similar, therefore indicating
that a redistribution of carnitine from its free form to an esterified
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Fig. 2. A. Renal clearance of total, free, acelyl-, medium- and long-chain
acylcarnitine (mi/mm) in continuous ambulatoty peritoneal dialysis patients (,
C.4PD) and age- and sex-matched healthy controls (1). Urine collections were
made over 24 hours. Values represent means SCM. *P < 0.05, **p < 0.01,
significantly different from controls. B. Peritoneal clearance of total, free,
acetyl-, medium- and long-chain acylcarnitine (mI/mm) in continuous ambu-
latory peritoneal dialysis patients (CAPD). Peritoneal dialysis fluid collections
were made over 24 hours. Values represent means SCM. C. Cumulative
(renal+peritoneal) clearances of total, free, acetyl-, medium- and long-chain
acylcamitine (mI/mm) in continuous ambulatory peritoneal dialysis patients(APD) and age- and sex-matched healthy controls. Urine and peritoncal
dialysis fluid collections were made over 24 hours. Values represent means
SCM. *p < 0.05; P < 0.01, significantly different from controls.
form occurred in the CAPD patients. Thirdly, this redistribution
of carnitine in CAPD patients, which has previously been re-
ported [7], was reflected solely by an increase in plasma medium-
and long-chain acylcarnitine concentrations.
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Fig. 3. A. Daily renal losses of total, free, acetyl-, medium- and long-chain
acylcarnitine in continuous ambulatory peritoneal dialysis patients (,
CAPD) and age- and sex-matched healthy controls (12). Values represent
means SCM. < 0.01, significantly different from controls. B. Daily
peritoneal losses of total, free, acetyl-, medium- and long-chain acylcar-
nitine in continuous ambulatory peritoneal dialysis patients (CAPD).
Values represent means SEM. C. Daily cumulative losses (urine and
pcritoneal dialysis fluid) of total, free, acetyl-, medium- and long-chain
acylcarnitine in continuous ambulatory peritoneal dialysis patients(CAPD) and age- and sex-matched healthy controls. Values represent
means SCM. < 0.05, < 0.01, significantly different from controls.
Carnitine is present in both plasma and urine in free and
esterified forms. Plasma free carnitine concentration which is age-
and sex-related [15, 16] normally represents 80% of the total
carnitine concentration (Fig. 1). The remaining 20% comprise the
csterified fraction, of which about —70% exists in the acetylated
form (Fig. 1). However, a redistribution of plasma free carnitine
to the esterified form has been reported to occur in disease [19,
201, fasting [21], and during exercise [22]. This is thought to result
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from carnitine's ability to buffer increases in tissue acyl group
levels [2]. In agreement with this latter function, the present study
showed that a similar redistribution of plasma free carnitine into
an esterified form occurred in the plasma of CAPD patients. This
contributed to a significantly lower free to total carnitine ratio in
the plasma of CAPD patients compared with controls (0.67 0.03
and 0.84 0.03, respectively; P C 0.01) and to a significantly
greater total acyl to free carnitine ratio (0.52 0.08 and 0.20
0.05, respectively; P C 0.01). These abnormal ratios have been
cited as a possible cause of a "relative carnitine deficiency" [23,
24]. However, the novel finding of the present study was that this
redistribution of plasma free carnitine into an esterified form in
the CAPD patients was reflected solely by an increase in plasma
medium- and long-chain acylcarnitine concentrations (Fig. 1). It is
worth mentioning that this change is in contrast to what it is seen
in conditions of human ketosis resulted from decreased insulin
secretion, where the redistribution is reflected mainly by an
increase in short-chain acylcarnitines [20, 21]. Since acetylcarni-
tine was the major plasma carnitine ester in the control subjects,
this change in the profile of plasma carnitine esters in CAPD
patients may reflect an impairment of acyl group oxidation
occurring in this patient population. Indeed, the intravenous
supplementation of plasma with carnitine in hemodialysis patients
has been shown to increase markedly not only plasma free
carnitine but also total acylcarnitine concentrations, resulting in
their ratio continuing to be abnormal [7]. This suggests that there
is an excess of acyl groups which are buffered by the administered
carnitine. Possible sites for this type of occurrence could be liver
where it is thought that an elevation of acyl groups, arising
primarily from an impairment of their oxidation, would be
buffered by carnitine. It has been suggested that plasma and liver
can exchange free carnitine for esterified forms during cellular
metabolic stress [22].
There is no evidence to suggest, at least for healthy subjects,
that an exchange of esterified carnitine for the free carnitine
occurs between skeletal muscle and plasma, as it has been shown
that during metabolic stress (muscle contraction) the decline in
muscle free carnitine was well matched by similar increases in
muscle carnitine esters, mainly acetylcarnitine [3, 22]. Therefore,
an alternative explanation for the present findings could be that
there was a slower and/or less efficient clearance of medium- and
long-chain aeylcarnitine by nephrons and/or across the peritoneal
cavity in the CAPD patients. It is not completely clear what effect
a slower rate of medium- and long-chain acylcarnitine excretion
would have upon the metabolism of CAPD patients. Since
acylcarnitines and aeyl-CoAs are in equilibrium via earnitine
acyltransferases [25] an accumulation of the former could serve as
a reservoir of acyl groups for acyl-CoA formation. Acyl-CoA
compounds, especially long-chain acyl groups, have deleterious
effects on cellular membrane integrity due to their detergent
properties [26] and have been shown to have an inhibitory effect
on adenine nucleotide translocation [27]. These effects may
account for some of the pathophysiology of chronic renal failure,
including atherosclerotic cardiovascular disorders.
A second aim of the present study was to quantify the daily
losses of free and esterified earnitine in CAPD patients. The daily
loss of total earnitine measured via analysis of urine and dialysis
fluids was not different in CAPD patients when compared with
controls (Fig. 3C). However, the daily loss of free carnitine in
CAPD patients was 1.7-fold greater than that of controls (P C
0.05). The principal route for this increased loss was via peritoneal
dialysis fluid, since the magnitude of loss was fivefold greater than
that via urine excretion (Fig. 3 A, B). CAPD patients also experi-
enced a significantly greater daily loss of acetylcarnitine (Fig. 3C).
However, the increased elimination of free carnitine and acetyl-
earnitine was matched by a similar decrease in the extent of
medium- and long-chain acylearnitine loss. The ratio of total
aeylearnitine to free carnitine in daily fluid losses (urine +
peritoneal dialysis fluid) were significantly lower in CAPD pa-
tients compared with controls (0.50 0.05 and 1.36 0.14,
respectively; P C 0.001). These findings could possibly be ex-
plained by differences in clearance rates. In controls, the total
acylcarnitine renal clearance was eightfold greater than that of
free earnitine (16.87 3.88 and 2.15 0.41 mI/mm, respectively),
which was probably attributable to the preferential renal tubular
reabsorbtion of free carnitine. In CAPD patients, however, the
cumulative peritoneal and renal clearance of acylearnitine was
similar to that of free earnitine (4.87 0.78 and 4.43 0.63
mI/mm, respectively; Fig. 2C). These data also showed that the
free earnitine peritoneal clearance (3.77 0.70) was actually
greater then the free earnitine renal clearance in controls (2.15
0.41). This may be attributable to a differential loss of the free
form across the peritoneal cavity resulting from the more rapid
diffusion of small molecules like free and acetylearnitine. It has
previously been shown that endogenous medium size molecules
(350 to 2,000 Daltons) are more efficiently transferred during
CAPD than during other forms of dialysis treatment [28].
Although the daily acetylearnitine losses by CAPD patients
were significantly greater than by controls (Fig. 3C), the respective
plasma levels differed only slightly (Fig. 1) and it seems unlikely
that the greater daily losses were directly harmful. However,
because of the potential deleterious effects of long-chain acyl-
CoA accumulation discussed previously, it may be of more
metabolic significance that the plasma level of medium- and
long-chain aeylearnitine of CAPD patients was three times greater
than that of controls (Fig. 1).
In conclusion, the present results demonstrate that the plasma
total earnitine concentration and the daily loss of total carnitine
were similar when comparing CAPD patients with age- and
sex-matched controls. However, the plasma concentration of free
carnitine was lower in CAPD patients than in controls and,
conversely, the daily loss of free earnitine was greater. The ratio of
total aeylearnitine to free earnitine was significantly greater in
plasma of CAPD patients than in controls and lower in daily fluid
losses. These ratio differences may have resulted from an ex-
change of plasma free earnitine with hepatic medium- and long-
chain acylcarnitines and/or to a differential loss of free earnitine
and aeylearnitine across the peritoneal cavity. Finally, given the
likely rise in the concentration of plasma medium- and long-chain
aeylearnitines as a result of earnitine therapy [7], our observations
suggest a need for some caution in the use of earnitine supple-
mentation in CAPD patients, until more is known of the meta-
bolic consequences relating to the accumulation of these com-
pounds.
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